



**I-MOVE
13th annual meeting**

**Virtual sessions between
16 and 30 September 2020**

Draft agenda

Quick overview

| Approximate Time (CEST) | 16th Sept (Wednesday) | 18th Sept (Friday) | 28th Sept (Monday) | 29th Sept (Tuesday) | 30th Sept (Wednesday) |
|-------------------------|---|---|---|--|---|
| 9:00-10:20 | | | Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates | | |
| 14:00-16:45 | Session I: 2019–20 influenza VE results from 5.1.2a studies | | Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for 5.1.2a and beyond | Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for 5.1.2a and beyond | Session VII + VIII: Laboratory challenges + Influenza brand/type-specific studies |
| 16:00-18:30 | | Session II: 5.1.2a 2019–20 influenza VE studies and approaches to COVID-19 surveillance | | Session VI: Influenza vaccine and COVID-19 | |

Alternative time zones¹:

| | 9:00-10:20 CEST | 14:00-16:45 CEST | 16:00-18:30 CEST |
|----------------------------------|-----------------|------------------|---------------------|
| WEST (5.1.2a 5.1.2a 5.1.2a time) | 8.00-9.30 | 13.00-15.45 | 15.00-17.30 |
| EEST (5.1.2a 5.1.2a time) | 10.00-11.30 | 15.00-17.45 | 17.00-19.30 |
| 5.1.2a | 15.00-16.30 | 20.00-22.45 | 22.00-00.30 (+1) |
| 5.1.2a | 18.00-19.30 | 23.00-25.30 | 1.00 (+1)-3.30 (+1) |
| 5.1.2a | 1.00-2.30 | 6.00-8.45 | 8.00-10.30 |
| 5.1.2a | 3.00-4.30 | 8.00-10.45 | 10.00-12.30 |
| 5.1.2a 5.1.2a 5.1.2a | 4.00-5.30 | 9.00-11.45 | 11.00-13.30 |

Detailed agenda

¹ Some of these times are at antisocial hours for some of our international colleagues. We will endeavour to record sessions so that colleagues can view the presentations at a more convenient time.

buiten verzoek

9:05 - 10:20 **Session III: Influenza and COVID-19 co-circulation – experience from the Southern Hemisphere and subtropical climates**

Moderators:

- Measuring influenza VE during SARS-CoV-2 co-circulation – results, challenges and lessons learnt, 15 min (5.1.2e)
- Measuring influenza VE during SARS-CoV-2 co-circulation – the experience from (5.1.2a) 15 min (5.1.2e)
- Influenza/ARI and COVID-19 cases in (5.1.2a) and timing of social distancing measures: results from surveillance data, 15 min (5.1.2e)
- Discussion, 30 min

Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond

28th of September, Monday; 14:00–16:15 CEST

14:00 - 14:05 **Welcome and introduction** (ECDC, Epicconcept)

14:05 - 15:05 **Session IV: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond**

Moderators:

- **Primary care: Adapting the influenza sentinel surveillance system to both COVID-19 surveillance and measuring influenza vaccine effectiveness**
 - The experience from (5.1.2a) 10 min (5.1.2e) (5.1.2e)
 - The experience from (5.1.2a) 10 min (5.1.2e) (5.1.2e)
 - The experience from (5.1.2a) 10 min (5.1.2e)
- Discussion, 30 min

15:05 – 15:15 Comfort break

15:15 – 16:15 **Session IV continued: Influenza and COVID-19 co-circulation: challenges and plans at primary care level for (5.1.2e) and beyond**

Moderators:

- **Primary care sentinel system challenges and approaches for the 2020–21 season: burden on health-care systems, influenza vaccine supply, surveillance, adaptation of platforms to measure COVID-19 interventions**
 - Reflections from (5.1.2a) 10 min (5.1.2e)
 - Reflections from (5.1.2a) 10 min (PHS team)
 - Reflections from the (5.1.2a) 10 min (the (5.1.2e) team)
- Discussion, 30 min

Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (5.1.2e) and beyond

29th of September, Tuesday; 14:00–16:05 CEST

14:00-14:05 **Welcome and introduction** (ECDC, Epicconcept)

14:05 - 15:05 **Session V: Influenza and COVID-19 co-circulation: challenges and plans at hospital level for (5.1.2a) and beyond**

Moderators:

- **Hospital: Coping with COVID-19 surveillance and measuring 2019–20 influenza vaccine effectiveness**
 - Reflections from 5.1.2a 10 min 5.1.2e 5.1.2e
 - Reflections from 5.1.2a, 10 min 5.1.2e
 - Reflections from 5.1.2a 10 min 5.1.2e
 - Discussion, 30 min
- 15:05 – 15:15 Comfort break
- 15:15 – 15:55 **Session V continued: SARI surveillance plans for the future**
- Moderators:
- **SARI surveillance and respiratory pathogen vaccine effectiveness in the WHO 5.1.2a region, WHO/Euro, 10 min (WHO/Euro team)**
 - TBC, 10 min, ()
 - Discussion, 20 min
- 15:55 – 16:05 Comfort break (note that session VI follows on directly after the break)

Session VI: Influenza vaccine and COVID-19

29th of September, Tuesday; 16:05–16:45 CEST

16:05 - 16:45 **Session VI: Influenza vaccine and COVID-19**

Moderators:

- Influenza vaccine does not increase the risk of coronavirus – results from 5.1.2a 10 min 5.1.2e
- Association between influenza vaccine and COVID-19 at primary care level – preliminary results from 5.1.2a 10 min (5.1.2e)
- Discussion, 20 min

buiten verzoek